PDCD1 and cancer: The pathogenesis of cutaneous immune-related adverse events (irAEs) observed in patients with cancer treated with immune checkpoint inhibitors remains variable, with one critical determinant being whether patients are treated with PD-1, PD-L1, and CTLA-4 antibodies (65, 66).